HIV
Conditions
Interventions
experimental group:ABT 320mg ivgtt (Day 1 and Day 15))+DTG 50mg po qd
control group:TDF 300mg po qd / 3TC 300mg po qd or TDF 300mg po qd/FTC 200mg po qd+DTG 50mg po qd
Sponsors
Public Health Clinical Center of Chengdu
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Male aged over 18 years; 2.HIV exposure: having male or male homosexual sex and meeting the requirements of exposure risk assessment stipulated in technical Guidelines for Post-EXPOSURE Prevention of HIV (Trial) issued by The Center for STD/AIDS Prevention and Control, Chinese Center for Disease Control and Prevention; 3.Self-exposure occurred within 72 hours of the first dose; 4.With negative HIV antibody test at the initiation of treatment; 5.Provide signed informed consent and be able to cooperate with and participate in all aspects of the study, including the use of iv drugs, completion of all evaluations, visits to designated study centers, and compliance with all protocol requirements.
Exclusion criteria
Exclusion criteria: 1.Known exposure source person is HIV negative; 2.Known intolerance or allergy to the drugs or excipients used in this study; 3.Upon the investigator's determination, the subject may have any potential circumstance negatively impacting on treatment adherence, safety and effecacy evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of subjects who completed 28 days of prophylactic medication; | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of adverse events (AE) and serious adverse events (SAE) ;Adherence to the regimen;HIV sero-conversion at 28 days and 12 weeks after exposure; | — |
Countries
China
Contacts
Public ContactHe Shenghua
Public Health Clinical Center of Chengdu
Outcome results
None listed